|
||
| |||||||
|
|
January 23rd 2006: ImmunoBiology Ltd. is pleased to announce the closing of its Series C funding round. The round was led by Inventages Venture Capital Investments Inc. Biosciences VTC also joined this funding round, along with all of ImmBio’s prior investors - Avlar BioVentures, Oxford Technology VCT and funds managed by Generics Asset Management and Yorkshire Fund Managers. Eight million Euros has been raised, with provision for follow on capital. Dr. Robert Schier, Partner of Inventages notes “ImmunoBiology’s technology leads to polyclonal immunity across a wide variety of viral and bacterial strains and is therefore very well suited for tackling some of the most challenging tasks in protecting people from life-threatening infectious disease. We believe that the highly experienced management team of the company will be able to transform the promises of its technology into safe and efficacious solutions to prevent and treat major diseases like Influenza, Tuberculosis and Hepatitis.” Graham Clarke, CEO of ImmBio comments: “Having established proof of principle of the broad-based utility of the technology platform, this funding will enable ImmBio to progress its candidates into pre-clinical development”. The technology platform (HspC™) is based on Heat Shock Protein Complexes (HspCs), which play the pivotal role of bridging between the innate and adaptive immunological response. The approach is expected to result in products with a broader, faster and safer profile compared with existing and new vaccines. The work on Influenza includes studies of protection against major strain change, the current concern with avian ‘flu. ImmBio’s candidates have demonstrated protection, providing a robust basis for polyclonal immunity, required to address both gradual strain drift and strain shift. There is now widespread recognition of the risk posed from strain shift, potentially leading to global pandemic, due to lack of immunity. Contact: Please direct enquiries to: Graham Clarke +44 (0)1223 496117 graham.clarke@immunobiology.co.uk About ImmunBiology Ltd ImmBio is focused on developing breakthrough products for prevention and treatment against life-threatening infections. It was founded in 1999 by Dr Camilo Colaco, based on new insights into the role of dendritic cells in immunology. Based at the Babraham Bioscience Research Campus, Cambridge (UK), work is conducted at its facilities, as well as with a number of collaborators. Initially with seed corn funding, ImmBio also secured two DTI SMART awards, before raising additional funds in 2003. This was applied to the establishment of proof of principle of the use of HspC in Tuberculosis and Influenza to generate lead candidates, as well as exploratory studies against selected other pathogens. About Inventages Investment Capital Inc. Inventages Venture Capital is a fund management company specializing in life sciences, with business offices in the Bahamas, Switzerland and New Zealand. It currently manages five funds, with a total of approximately EUR 1 billion. The first fund supports pharmaceutical and biotech companies. Funds two to five have with a strong focus on prevention, raised between 2002 and 2005 with strategic partners as cornerstone investors, notably Nestlé SA. Inventages concentrates on selective investments in the field of disease prevention and chronic disease management. Portfolio companies are intensively supported and can leverage the deep business experiences and strong relationships of the Inventages' partners within the global pharmaceutical, cosmetics, food and biotech industries.
ImmunoBiology Limited,
|
|
| ||||||||
